Sanofi-Aventis discontinues two Phase II candidates
This article was originally published in Scrip
Executive Summary
Sanofi-Aventishas announced the discontinuation of AVE2268, an oral SGLT-2 inhibitor intended for treatment of type 2 diabetes, and surinabant, a cannabinoid 1 (CB-1) receptor antagonist for smoking cessation and obesity, due to lack of efficacy, during the release of its third quarter results. Both drugs were in Phase II trials.